Patent intelligence · US
US 11285210
Buffer formulations for enhanced antibody stability
Buffer formulations for enhanced antibody stability
Patent details — US 11285210
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2022
- Expiration
- Mar 24, 2042
- Applicant
- Outlook Therapeutics, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K2039/54, A61K39/39591, A61K47/12
Quick answer
US 11285210 (Buffer formulations for enhanced antibody stability) is held by Outlook Therapeutics, Inc.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Outlook Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/54, A61K39/39591, A61K47/12, A61K47/183, A61K47/26
More from Outlook Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11285210?
US 11285210 (Buffer formulations for enhanced antibody stability) is held by Outlook Therapeutics, Inc.. Status: granted. Granted Mar 29, 2022. Expires Mar 24, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11285210?
Outlook Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 11285210 expire?
Our index shows an expiration date of Mar 24, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.